These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19896588)

  • 1. Can we do better in developing new drugs for Alzheimer's disease?
    Gauthier S; Scheltens P
    Alzheimers Dement; 2009 Nov; 5(6):489-91. PubMed ID: 19896588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pathology and pharmacogenomics in Alzheimer's disease: polygenic-related effects of multifactorial treatments on cognition, anxiety and depression.
    Cacabelos R
    Methods Find Exp Clin Pharmacol; 2007 Jul; 29 Suppl A():1-91. PubMed ID: 17957277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan.
    Nozawa M; Ichimiya Y; Nozawa E; Utumi Y; Sugiyama H; Murayama N; Iseki E; Arai H
    Psychogeriatrics; 2009 Jun; 9(2):50-5. PubMed ID: 19604325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dementing disorders. What benefits do the new anti-dementia drugs have?].
    Ihl R
    MMW Fortschr Med; 2002 May; Suppl 2():24-6, 28-9. PubMed ID: 12070846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ApoE genotype on response to donepezil in patients with Alzheimer's disease.
    Choi SH; Kim SY; Na HR; Kim BK; Yang DW; Kwon JC; Park MY
    Dement Geriatr Cogn Disord; 2008; 25(5):445-50. PubMed ID: 18401173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of donepezil for mild to moderate Alzheimer's disease in Taiwan.
    Fuh JL; Wang SJ
    Int J Geriatr Psychiatry; 2008 Jan; 23(1):73-8. PubMed ID: 17520661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Realistic expectations for treatment success in Alzheimer's disease.
    Geldmacher DS; Frolich L; Doody RS; Erkinjuntti T; Vellas B; Jones RW; Banerjee S; Lin P; Sano M
    J Nutr Health Aging; 2006; 10(5):417-29. PubMed ID: 17066215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?
    Cortes F; Portet F; Touchon J; Vellas B
    J Nutr Health Aging; 2007; 11(4):330-7. PubMed ID: 17653493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anti-dementia drugs for dementia syndromes--just unkept promises?].
    Ihl R
    MMW Fortschr Med; 2006 May; Spec no. 2():24-6. PubMed ID: 20104710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
    Prasher VP
    Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Centers of excellence in Alzheimer's disease: it is time to better integrate patient care and clinical research to improve the prevention and treatment of Alzheimer's disease.
    Doody RS
    Alzheimers Dement; 2009 Mar; 5(2):133-6. PubMed ID: 19328443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practice guidelines for the diagnosis and treatment of Alzheimer's disease in a managed care setting: Part II--Pharmacologic therapy. Alzheimer's Disease (AD) Managed Care Advisory Council.
    Fillit H; Cummings J
    Manag Care Interface; 2000 Jan; 13(1):51-6. PubMed ID: 10747691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease: clinical treatment options.
    Reichman WE
    Am J Manag Care; 2000 Dec; 6(22 Suppl):S1125-32; discussion S1133-8. PubMed ID: 11142177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?
    Sevilla C; Jiménez Caballero PE; Alfonso V; González-Adalid M
    Dement Geriatr Cogn Disord; 2009; 28(3):196-205. PubMed ID: 19738386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Who may benefit from disease-modifying studies in Alzheimer's disease?
    Gauthier S; Poirier J
    Alzheimers Dement; 2009 Mar; 5(2):147-8. PubMed ID: 19328447
    [No Abstract]   [Full Text] [Related]  

  • 17. Do cholinesterase inhibitors slow progression of Alzheimer's disease?
    Farlow MR
    Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D; Andersen HF
    Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis.
    Jelic V; Haglund A; Kowalski J; Langworth S; Winblad B
    Dement Geriatr Cogn Disord; 2008; 26(5):458-66. PubMed ID: 18984956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tacrine].
    Dávila C; Viteri C; de Castro P
    Rev Med Univ Navarra; 1997; 41(1):58-64. PubMed ID: 9527715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.